Department of Cardiothoracic Surgery, Heart Center of the University of Cologne, Cologne, Germany.
Thorac Cardiovasc Surg. 2024 Jun;72(4):296-299. doi: 10.1055/a-2132-4694. Epub 2023 Jul 18.
Surgically implanted Impella 5.5. delivers full cardiac support and left ventricular unloading for patients with heart failure. So far, the Impella device is implanted under general anesthesia (GA).
A total of = 3 critically ill patients presented with acute heart failure in need of cardiac support. All patients suffered cardiogenic shock of varying etiology. Due to hemodynamically unstable conditions, GA was avoided. All implantations were performed solely under local anesthesia (LAS) without any regional anesthesia.
All implantations were performed successfully under LAS with 60 mL of mepivacaine of 2% solution and ropivacaine of 1% solution (50:50 ratio). All devices were placed from the right axillary artery. One patient needed hematoma evacuation several days after surgery. No other Impella-related complication was observed.
A surgical implantation of the Impella 5.5 device under LAS is feasible and safe. Despite the small number of cases, no disadvantage can be described at the present moment. Our series should encourage physicians to perform the procedure under LAS.
植入式 Impella 5.5 可向心力衰竭患者提供全面的心脏支持和左心室卸载。到目前为止,Impella 设备是在全身麻醉(GA)下植入的。
共有 3 名危重症患者因急性心力衰竭需要心脏支持而就诊。所有患者均患有不同病因的心源性休克。由于血流动力学不稳定,避免了 GA。所有植入均仅在局部麻醉(LAS)下进行,而不使用任何区域麻醉。
所有植入均在 LAS 下成功完成,使用 2%甲哌卡因和 1%罗哌卡因的 60 毫升溶液(50:50 比例)。所有设备均从右腋动脉放置。一名患者在手术后几天需要清除血肿。未观察到其他与 Impella 相关的并发症。
在 LAS 下进行 Impella 5.5 设备的外科植入是可行且安全的。尽管病例数量较少,但目前尚无不利之处。我们的系列研究应该鼓励医生在 LAS 下进行该手术。